Biosynthesis and medicinal chemistry of the capuramycin antimycobacterial antibiotics
辣椒霉素抗分枝杆菌抗生素的生物合成和药物化学
基本信息
- 批准号:9246017
- 负责人:
- 金额:$ 20万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-01-01 至 2021-12-31
- 项目状态:已结题
- 来源:
- 关键词:AchievementAcidsAddressAnabolismAntibioticsAntimycobacterial AgentsAntitubercular AgentsApplied ResearchBiologicalBiological AvailabilityCell WallCessation of lifeChemicalsChinaClinicalCollaborationsCommunicable DiseasesCountryDevelopmentDiseaseDrug resistanceDrug resistance in tuberculosisEngineeringEnzymesFamilyFosteringFunding MechanismsFutureGoalsHealthHexuronic AcidsHumanIn VitroIncidenceIndiaIndividualLeadLibrariesModificationMulti-Drug ResistanceMultidrug-Resistant TuberculosisMusMycobacterium tuberculosisNatural ProductsNucleosidesOpen Reading FramesPeptidoglycanPharmaceutical ChemistryPharmaceutical PreparationsPharmacologyPharmacotherapyPhosphotransferasesPopulationPreparationProductionPropertyReactionRecoveryReportingResearchResistanceRifampinSeriesSourceStructureSubstrate SpecificitySugar SubstituteSystemTechnologyTherapeuticToxic effectTreatment ProtocolsTuberculosisUnited StatesUridineWorld Health Organizationanalogbactericidechemical functionclinical developmentdrug developmentdrug discoveryextensive drug resistancefightingfundamental researchglycosyltransferaseimprovedin vitro activityin vivoinhibitor/antagonistinnovationisoniazidkillingsnanomolarnovelpathogenpermissivenesspharmacophoreresistance mechanismresistant strainscaffoldsugartooltranslocasetuberculosis drugstuberculosis treatmentvirtual
项目摘要
Tuberculosis (TB)—which is primarily caused by the bacterial pathogen Mycobacterium tuberculosis (Mtb)—is
an ancient disease that remains one of the deadliest communicable diseases worldwide. A paramount concern
heading into the future is the rapid rise in drug-resistant TB. The World Health Organization estimated 480,000
cases of TB with 190,000 deaths in 2014 with resistance to the first-line anti-TB drugs isoniazid and rifampicin.
Furthermore, totally drug-resistant Mtb has now been documented in multiple countries including the United
States. The capuramycin family of glycosylated nucleoside antibiotics are excellent candidates for anti-TB drug
discovery and development because they (i) are considered new chemical entities with several unusual structural
features compared to all antibiotics including clinical anti-TB drugs, (ii) target a novel and essential enzyme
(translocase 1; TL1) in cell wall biosynthesis, (ii) have exceptional anti-Mtb activity in vitro and in vivo, (iv) are
bactericidal and kill Mtb faster than any first-line anti-TB drug in vitro, and (v) have no toxicity. Our primary
objectives in this proposal are to define a biosynthetic mechanism for the assembly of the unusual unsaturated
hexuronic acid component in capuramycins (Aim 1) and establish complementary chemical (via
neoglycorandomization; Aim 2) and biosynthetic (via native and nonnative glycosyltransferases; Aim 3) platforms
for rapidly generating novel hexuronic acid-substituted capuramycins that can be screened for TL1 inhibition,
anti-Mtb activity, and improved pharmacological properties. Additionally, these novel capuramycin analogues
will be screened as potential substrates or inhibitors of the phosphotransferase CapP, which covalently modifies
capuramycin as a strategy of self-resistance within the producing strain and is potentially a widespread
resistance mechanism. It is expected that, upon completion of the aims, a new biosynthetic mechanism for sugar
incorporation and modification will be defined. Furthermore, the completion of the aims will provide the first
practical, comprehensive strategy to rapidly interrogate/modulate the fundamental features of capuramycin core
pharmacophore, which will not only be important for the clinical development of capuramycin but can be applied
to other glycosylated nucleoside antibiotics, of which dozens are now known with diverse biological activities.
结核病(TB)--主要由细菌病原体结核分枝杆菌(Mtb)引起--
这种古老的疾病仍然是世界上最致命的传染病之一。最令人担忧的问题
面向未来的是耐药结核病的快速增长。世界卫生组织估计有48万人
2014年,对一线抗结核药物异烟肼和利福平耐药的结核病病例有19万人死亡。
此外,包括美国在内的多个国家已经记录了完全耐药的结核分枝杆菌。
各州。卡普拉霉素家族糖基化核苷类抗生素是抗结核药物的极佳候选药物
发现和发展,因为它们(I)被认为是具有几个不寻常结构的新的化学实体
与包括临床抗结核药物在内的所有抗生素相比的特点:(Ii)针对一种新的和必要的酶
(转位酶1;TL1)在细胞壁生物合成中,(Ii)在体外和体内具有优异的抗结核分枝杆菌活性,(Iv)是
在体外杀菌和杀死结核分枝杆菌的速度比任何一线抗结核药物都要快,并且(V)没有毒性。我们的初选
这项提案的目标是定义一种生物合成机制,用于组装不寻常的不饱和脂肪酸
卡普拉霉素中的己糖醛酸成分(目标1)和建立互补化学物质(通过
新糖随机化;目标2)和生物合成(通过天然和非天然糖基转移酶;目标3)平台
为了快速产生可筛选TL1抑制的新型己糖醛酸取代的卡普拉霉素,
抗结核分枝杆菌活性,改善药理特性。此外,这些新的卡普拉霉素类似物
将被筛选为磷酸转移酶CAPP的潜在底物或抑制剂,该酶可共价修饰
卡普拉霉素作为产生菌内的一种自我抗性策略,具有广泛的应用前景
抗性机制。预计在完成目标后,糖的新的生物合成机制
将对合并和修改进行定义。此外,这些目标的完成将提供第一个
快速询问/调整卡普拉霉素核心基本特征的实用、全面的策略
药效团,这不仅对卡普拉霉素的临床开发具有重要意义,而且可以应用于
到其他糖基化核苷抗生素,其中数十种现在已知具有不同的生物活性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jon Scott Thorson其他文献
Jon Scott Thorson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jon Scott Thorson', 18)}}的其他基金
Administrative Supplement: COBRE in Pharmaceutical Research and Innovation
行政补充:COBRE 药物研究与创新
- 批准号:
10399734 - 财政年份:2021
- 资助金额:
$ 20万 - 项目类别:
Administrative Supplement: COBRE in Pharmaceutical Research and Innovation
行政补充:COBRE 药物研究与创新
- 批准号:
10582060 - 财政年份:2020
- 资助金额:
$ 20万 - 项目类别:
Center of Biomedical Research Excellence in Pharmaceutical Research and Innovation
药物研究与创新卓越生物医学研究中心
- 批准号:
10333385 - 财政年份:2020
- 资助金额:
$ 20万 - 项目类别:
Administrative Supplement: COBRE in Pharmaceutical Research and Innovation
行政补充:COBRE 药物研究与创新
- 批准号:
10794454 - 财政年份:2020
- 资助金额:
$ 20万 - 项目类别:
Center of Biomedical Research Excellence in Pharmaceutical Research and Innovation
药物研究与创新卓越生物医学研究中心
- 批准号:
10569658 - 财政年份:2020
- 资助金额:
$ 20万 - 项目类别:
Center of Biomedical Research Excellence in Pharmaceutical Research and Innovation
药物研究与创新卓越生物医学研究中心
- 批准号:
10112923 - 财政年份:2020
- 资助金额:
$ 20万 - 项目类别:
Developing Regeneration Resources for a Model Amphibian
为模型两栖动物开发再生资源
- 批准号:
9272459 - 财政年份:2016
- 资助金额:
$ 20万 - 项目类别:
相似国自然基金
具有抗癌活性的天然产物金霉酸(Aureolic acids)全合成与选择性构建2-脱氧糖苷键
- 批准号:22007039
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
海洋放线菌来源聚酮类化合物Pteridic acids生物合成机制研究
- 批准号:
- 批准年份:2019
- 资助金额:10.0 万元
- 项目类别:省市级项目
手性Lewis Acids催化的分子内串联1,5-氢迁移/环合反应及其在构建结构多样性手性含氮杂环化合物中的应用
- 批准号:21372217
- 批准年份:2013
- 资助金额:80.0 万元
- 项目类别:面上项目
对空气稳定的新型的有机金属Lewis Acids催化剂制备、表征与应用研究
- 批准号:21172061
- 批准年份:2011
- 资助金额:30.0 万元
- 项目类别:面上项目
钛及含钛Lewis acids促臭氧/过氧化氢体系氧化性能的广普性、高效性及其机制
- 批准号:21176225
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
基于Zip Nucleic Acids引物对高度降解和低拷贝DNA检材的STR分型研究
- 批准号:81072511
- 批准年份:2010
- 资助金额:31.0 万元
- 项目类别:面上项目
海洋天然产物Makaluvic acids 的全合成及其对南海鱼虱存活的影响
- 批准号:30660215
- 批准年份:2006
- 资助金额:21.0 万元
- 项目类别:地区科学基金项目
相似海外基金
CAREER: Highly Rapid and Sensitive Nanomechanoelectrical Detection of Nucleic Acids
职业:高度快速、灵敏的核酸纳米机电检测
- 批准号:
2338857 - 财政年份:2024
- 资助金额:
$ 20万 - 项目类别:
Continuing Grant
Lipid nanoparticle-mediated Inhalation delivery of anti-viral nucleic acids
脂质纳米颗粒介导的抗病毒核酸的吸入递送
- 批准号:
502577 - 财政年份:2024
- 资助金额:
$ 20万 - 项目类别:
Double Incorporation of Non-Canonical Amino Acids in an Animal and its Application for Precise and Independent Optical Control of Two Target Genes
动物体内非规范氨基酸的双重掺入及其在两个靶基因精确独立光学控制中的应用
- 批准号:
BB/Y006380/1 - 财政年份:2024
- 资助金额:
$ 20万 - 项目类别:
Research Grant
Quantifying L-amino acids in Ryugu to constrain the source of L-amino acids in life on Earth
量化 Ryugu 中的 L-氨基酸以限制地球生命中 L-氨基酸的来源
- 批准号:
24K17112 - 财政年份:2024
- 资助金额:
$ 20万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Collaborative Research: RUI: Elucidating Design Rules for non-NRPS Incorporation of Amino Acids on Polyketide Scaffolds
合作研究:RUI:阐明聚酮化合物支架上非 NRPS 氨基酸掺入的设计规则
- 批准号:
2300890 - 财政年份:2023
- 资助金额:
$ 20万 - 项目类别:
Continuing Grant
Integrated understanding and manipulation of hypoxic cellular functions by artificial nucleic acids with hypoxia-accumulating properties
具有缺氧累积特性的人工核酸对缺氧细胞功能的综合理解和操纵
- 批准号:
23H02086 - 财政年份:2023
- 资助金额:
$ 20万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Basic research toward therapeutic strategies for stress-induced chronic pain with non-natural amino acids
非天然氨基酸治疗应激性慢性疼痛策略的基础研究
- 批准号:
23K06918 - 财政年份:2023
- 资助金额:
$ 20万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms how arrestins that modulate localization of glucose transporters are phosphorylated in response to amino acids
调节葡萄糖转运蛋白定位的抑制蛋白如何响应氨基酸而被磷酸化的分子机制
- 批准号:
23K05758 - 财政年份:2023
- 资助金额:
$ 20万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular recognition and enantioselective reaction of amino acids
氨基酸的分子识别和对映选择性反应
- 批准号:
23K04668 - 财政年份:2023
- 资助金额:
$ 20万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Synthetic analogues based on metabolites of omega-3 fatty acids protect mitochondria in aging hearts
基于 omega-3 脂肪酸代谢物的合成类似物可保护衰老心脏中的线粒体
- 批准号:
477891 - 财政年份:2023
- 资助金额:
$ 20万 - 项目类别:
Operating Grants